Merck & Co. Inc. (MRK) announced Tuesday morning that its Phase 3 trial of KEYTRUDA in combination with pemetrexed and cisplatin or carboplatin, for the first-line treatment of patients with metastatic non-squamous non-small cell lung cancer, met its dual primary endpoints of overall survival and progression-free survival.
from RTT - Before the Bell http://ift.tt/2EOfHDk
via IFTTT
No comments:
Post a Comment